PERSONALIS INC (PSNL) Stock Price & Overview
NASDAQ:PSNL • US71535D1063
Current stock price
The current stock price of PSNL is 6.02 USD. Today PSNL is down by -1.15%. In the past month the price decreased by -8.65%. In the past year, price increased by 83.82%.
PSNL Key Statistics
- Market Cap
- 630.174M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.91
- Dividend Yield
- N/A
PSNL Stock Performance
PSNL Stock Chart
PSNL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PSNL. When comparing the yearly performance of all stocks, PSNL is one of the better performing stocks in the market, outperforming 81.68% of all stocks.
PSNL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PSNL. PSNL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PSNL Earnings
On February 26, 2026 PSNL reported an EPS of -0.26 and a revenue of 17.34M. The company beat EPS expectations (13.04% surprise) and missed revenue expectations (-2.18% surprise).
PSNL Forecast & Estimates
13 analysts have analysed PSNL and the average price target is 11.66 USD. This implies a price increase of 93.64% is expected in the next year compared to the current price of 6.02.
For the next year, analysts expect an EPS growth of -19.29% and a revenue growth 12.94% for PSNL
PSNL Groups
Sector & Classification
PSNL Financial Highlights
Over the last trailing twelve months PSNL reported a non-GAAP Earnings per Share(EPS) of -0.91. The EPS increased by 33.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.32% | ||
| ROE | -31.12% | ||
| Debt/Equity | 0.01 |
PSNL Ownership
PSNL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 20 | 184.295B | ||
| DHR | DANAHER CORP | 22.33 | 134.187B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 138.05 | 45.413B | ||
| A | AGILENT TECHNOLOGIES INC | 17.12 | 32.516B | ||
| WAT | WATERS CORP | 22.01 | 31.392B | ||
| IQV | IQVIA HOLDINGS INC | 13.05 | 28.091B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 28.21 | 26.832B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.64 | 18.492B | ||
| ILMN | ILLUMINA INC | 23.11 | 18.49B | ||
| MEDP | MEDPACE HOLDINGS INC | 28.27 | 14.095B | ||
| RVTY | REVVITY INC | 16.32 | 10.039B | ||
| TECH | BIO-TECHNE CORP | 25 | 8.689B | ||
| CRL | CHARLES RIVER LABORATORIES | 15.77 | 8.667B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PSNL
Company Profile
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 260 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Company Info
IPO: 2019-06-20
PERSONALIS INC
6600 Dumbarton Circle
Fremont CALIFORNIA 94025 US
CEO: John West
Employees: 260
Phone: 16507521300
PERSONALIS INC / PSNL FAQ
Can you describe the business of PERSONALIS INC?
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 260 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Can you provide the latest stock price for PERSONALIS INC?
The current stock price of PSNL is 6.02 USD. The price decreased by -1.15% in the last trading session.
Does PERSONALIS INC pay dividends?
PSNL does not pay a dividend.
What is the ChartMill technical and fundamental rating of PSNL stock?
PSNL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy PSNL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PSNL.
Is PERSONALIS INC (PSNL) expected to grow?
The Revenue of PERSONALIS INC (PSNL) is expected to grow by 12.94% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of PSNL stock?
PERSONALIS INC (PSNL) has a market capitalization of 630.17M USD. This makes PSNL a Small Cap stock.